On the public citation graph

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer

https://doi.org/10.1371/journal.pone.0227256
0 signed · 94 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2017.9991openalex-snapshot
Multidimensional Evidence Generation and FDA Regulatory Decision Making
inferredcites →https://doi.org/10.1001/jama.291.22.2720openalex-snapshot
Participation in Cancer Clinical Trials
inferredcites →https://doi.org/10.1001/jamainternmed.2017.3919openalex-snapshot
Use of Health Care Databases to Support Supplemental Indications of Approved Medications
inferredcites →https://doi.org/10.1002/cpt.946openalex-snapshot
Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality
inferredcites →https://doi.org/10.1002/sim.5705openalex-snapshot
The performance of different propensity score methods for estimating marginal hazard ratios
inferredcites →https://doi.org/10.1002/sim.6607openalex-snapshot
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
inferredcites →https://doi.org/10.1002/sim.7084openalex-snapshot
Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/j.jval.2014.10.009openalex-snapshot
Optimizing the Leveraging of Real-World Data to Improve the Development and Use of Medicines
inferredcites →https://doi.org/10.1038/s41523-018-0054-xopenalex-snapshot
Characterization of bone only metastasis patients with respect to tumor subtypes
inferredcites →https://doi.org/10.1056/nejmoa1607303openalex-snapshot
Palbociclib and Letrozole in Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmp1614720openalex-snapshot
From Trial to Target Populations — Calibrating Real-World Data
inferredcites →https://doi.org/10.1056/nejmsb1609216openalex-snapshot
Real-World Evidence — What Is It and What Can It Tell Us?
inferredcites →https://doi.org/10.1080/00273171.2011.568786openalex-snapshot
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
inferredcites →https://doi.org/10.1089/blr.2007.9941openalex-snapshot
Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
inferredcites →https://doi.org/10.1093/jnci/djx187openalex-snapshot
Real-world Data for Clinical Evidence Generation in Oncology
inferredcites →https://doi.org/10.1177/0962280213519716openalex-snapshot
The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation study
inferredcites →https://doi.org/10.1177/0962280215584401openalex-snapshot
The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes
inferredcites →https://doi.org/10.1200/cci.19.00013openalex-snapshot
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set
inferredcites →https://doi.org/10.1200/po.17.00132openalex-snapshot
Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance
inferredcites →https://doi.org/10.21953/lse.anw9nzz3qqkpopenalex-snapshot
RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap
inferredcites →https://doi.org/10.4143/crt.2011.43.2.89openalex-snapshot
Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
inferredcites →https://doi.org/10.6004/jnccn.2020.0016openalex-snapshot
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5128524openalex-extracted
Immune Checkpoint Inhibitor Treatment - Real-World Overall Survival, Treatment Adoption Rates, and Regional Differences in Sweden
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.9286openalex-snapshot
Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC
inferred← citeshttps://doi.org/10.1002/cpt.2351openalex-snapshot
Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data
inferred← citeshttps://doi.org/10.1002/cpt.2454openalex-snapshot
Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men
inferred← citeshttps://doi.org/10.1002/cpt.3045openalex-snapshot
Real‐World Progression‐Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real‐World Data
inferred← citeshttps://doi.org/10.1002/cpt.70470openalex-snapshot
Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma
inferred← citeshttps://doi.org/10.1002/pds.5323openalex-snapshot
Differential frequency in imaging‐based outcome measurement: Bias in real‐world oncology comparative‐effectiveness studies
inferred← citeshttps://doi.org/10.1002/pds.5565openalex-snapshot
Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA ‐2 trial
inferred← citeshttps://doi.org/10.1002/pst.2115openalex-snapshot
Progression‐free survival in oncological clinical studies: Assessment time bias and methods for its correction
inferred← citeshttps://doi.org/10.1002/pst.2190openalex-snapshot
An adaptive design for early clinical development including interim decision for single‐arm trial with external controls or randomized trial
inferred← citeshttps://doi.org/10.1002/sim.9590openalex-snapshot
A proper statistical inference framework to compare clinical trial and real‐world progression‐free survival data
inferred← citeshttps://doi.org/10.1007/s10147-026-02978-4openalex-snapshot
Effectiveness of first-line combination chemotherapy in older patients with unresectable advanced gastric cancer: a retrospective study
inferred← citeshttps://doi.org/10.1007/s10549-024-07415-6openalex-snapshot
First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting
inferred← citeshttps://doi.org/10.1007/s11523-021-00826-1openalex-snapshot
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
inferred← citeshttps://doi.org/10.1007/s11523-023-00968-4openalex-snapshot
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
inferred← citeshttps://doi.org/10.1007/s11523-023-00979-1openalex-snapshot
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12325-021-01659-0openalex-snapshot
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC
inferred← citeshttps://doi.org/10.1007/s12561-022-09334-wopenalex-snapshot
A Simulation-Based Evaluation of Statistical Methods for Hybrid Real-World Control Arms in Clinical Trials
inferred← citeshttps://doi.org/10.1007/s40259-026-00768-yopenalex-snapshot
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France
inferred← citeshttps://doi.org/10.1016/j.breast.2023.01.007openalex-snapshot
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
inferred← citeshttps://doi.org/10.1016/j.breast.2026.104837openalex-snapshot
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence
inferred← citeshttps://doi.org/10.1016/j.canep.2022.102096openalex-snapshot
Development and validation of a coding framework to identify severe acute toxicity from systemic anti-cancer therapy using hospital administrative data
inferred← citeshttps://doi.org/10.1016/j.clbc.2026.04.012openalex-snapshot
Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.cllc.2021.12.009openalex-snapshot
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.cllc.2022.01.002openalex-snapshot
Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.drudis.2025.104324openalex-snapshot
The feasibility of using real world data as external control arms in oncology trials
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102029openalex-snapshot
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100254openalex-snapshot
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.esmorw.2024.100071openalex-snapshot
Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma
inferred← citeshttps://doi.org/10.1016/j.esmorw.2026.100789openalex-snapshot
Neoadjuvant versus adjuvant chemotherapy in luminal B-like breast cancer: a subset analysis of the CANTO study
inferred← citeshttps://doi.org/10.1016/j.eururo.2023.05.031openalex-snapshot
Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies
inferred← citeshttps://doi.org/10.1016/j.gore.2024.101440openalex-snapshot
Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience
inferred← citeshttps://doi.org/10.1016/j.lungcan.2023.107186openalex-snapshot
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
inferred← citeshttps://doi.org/10.1038/s41523-022-00479-xopenalex-snapshot
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
inferred← citeshttps://doi.org/10.1038/s41598-025-33530-5openalex-snapshot
Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer
inferred← citeshttps://doi.org/10.1080/13696998.2020.1840113openalex-snapshot
Using electronic health record data to identify comparator populations for comparative effectiveness research
inferred← citeshttps://doi.org/10.1080/14737167.2025.2467379openalex-snapshot
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024
inferred← citeshttps://doi.org/10.1093/jnci/djag291openalex-snapshot
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-derived external control arms
inferred← citeshttps://doi.org/10.1093/oncolo/oyae279openalex-snapshot
The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients
inferred← citeshttps://doi.org/10.1097/cmr.0000000000001101openalex-snapshot
Real-world recurrence-free and distant metastasis-free survival in early-stage melanoma: concordance with KEYNOTE-716 trial estimates
inferred← citeshttps://doi.org/10.1101/2022.05.02.22274571openalex-snapshot
Real-World Progression-Free Survival as an Endpoint in Advanced Non-Small-Cell Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Data Derived From Electronic Health Records
inferred← citeshttps://doi.org/10.1136/jitc-2022-004904openalex-snapshot
Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
inferred← citeshttps://doi.org/10.1136/jitc-2022-005801openalex-snapshot
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-22-0471openalex-snapshot
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
inferred← citeshttps://doi.org/10.1158/2767-9764.crc-25-0225openalex-snapshot
Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
inferred← citeshttps://doi.org/10.1177/0272989x231162852openalex-snapshot
Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation
inferred← citeshttps://doi.org/10.1177/1758835920968725openalex-snapshot
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study
inferred← citeshttps://doi.org/10.1177/1758835920980558openalex-snapshot
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
inferred← citeshttps://doi.org/10.1177/17588359221075495openalex-snapshot
A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
inferred← citeshttps://doi.org/10.1186/s13058-021-01409-8openalex-snapshot
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
inferred← citeshttps://doi.org/10.1200/op.20.00810openalex-snapshot
Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment
inferred← citeshttps://doi.org/10.1200/po-25-01272openalex-snapshot
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0278842openalex-snapshot
Transporting observational study results to a target population of interest using inverse odds of participation weighting
inferred← citeshttps://doi.org/10.1371/journal.pone.0285125openalex-snapshot
RWD-derived response in multiple myeloma
inferred← citeshttps://doi.org/10.21037/tlcr-21-32openalex-snapshot
Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies
inferred← citeshttps://doi.org/10.21203/rs.3.rs-8098549/v1openalex-snapshot
Real-World Event-Free Survival and Real-World Pathological Complete Response in Early-Stage Triple-Negative Breast Cancer: Concordance with Estimates from the control arm of the KEYNOTE-522 Trial
inferred← citeshttps://doi.org/10.2217/cer-2022-0006openalex-snapshot
A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms
inferred← citeshttps://doi.org/10.2217/fon-2020-0573openalex-snapshot
POLARIS: a Prospective, Multicenter, Noninterventional Study Assessing Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer
inferred← citeshttps://doi.org/10.2217/fon-2021-1229openalex-snapshot
Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma
inferred← citeshttps://doi.org/10.2217/fon-2022-0348openalex-snapshot
Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond)
inferred← citeshttps://doi.org/10.3389/fdsfr.2024.1423493openalex-snapshot
Measurement error and bias in real-world oncology endpoints when constructing external control arms
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1264912openalex-snapshot
Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
inferred← citeshttps://doi.org/10.3389/fonc.2024.1419246openalex-snapshot
Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series
inferred← citeshttps://doi.org/10.3390/cancers13030370openalex-snapshot
HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
inferred← citeshttps://doi.org/10.3390/cancers14112709openalex-snapshot
The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?
inferred← citeshttps://doi.org/10.3390/cancers15215268openalex-snapshot
Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
inferred← citeshttps://doi.org/10.6084/m9.figshare.14299440openalex-snapshot
Additional file 1 of Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
inferred← citeshttps://doi.org/10.6084/m9.figshare.14299443openalex-snapshot
Additional file 2 of Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
inferred← citeshttps://doi.org/10.6084/m9.figshare.14299446openalex-snapshot
Additional file 3 of Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
inferred← citeshttps://doi.org/10.6084/m9.figshare.14299449openalex-snapshot
Additional file 4 of Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
inferred← citeshttps://doi.org/10.7759/cureus.84020openalex-snapshot
Local Ablative Treatment of the Primary Tumour in Patients With Metastatic Breast Cancer: A Retrospective Observational Study
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.